Johnson & Johnson (JNJ DU) stock market data APIs
€149.5256
0.09(0.1%)
as of September 17, 2025
Try our APIs with
free plan!
Johnson & Johnson Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for JNJ.DU.
Prev. Close
149.5256
Open
149.615
High
148.904
Low
149.615
52 wk Range
128.084-158.5182
Market Cap
385 769 M
Dividends (Yield)
0.0222
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Johnson & Johnson data using free add-ons & libraries
Get Johnson & Johnson Fundamental Data
Johnson & Johnson Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Johnson & Johnson News
New
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks were edging up late Wednesday afternoon, with the NYSE Health Care Index up 0.2% PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB)
Genmab A/S (NASDAQ:GMAB) is one of the best affordable biotech stocks to invest in now. In a report released on September 8, Justin Smith from Bernstein reiterated a Sell rating on Genmab A/S (NASDA...
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
GSK plc GSK has unveiled a $30 billion investment plan in research and development (R&D) and supply chain infrastructure in the United States, which will be executed over the next five years. GSK’s...
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory
We came across a bullish thesis on Protagonist Therapeutics, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on PTGX. Protagonist Therapeutics...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
